PHARMAC documents that matched your search:
Health Minister Annette King says a national pharmaceutical purchasing strategy will provide consistency and equitable access to hospital drugs throughout New Zealand. Ms King has approved the National Hospital Pharmaceutical Purchasing Strategy, which will see Pharmac, the Government’s drug-buying agency, authorised to work collaboratively with individual DHBs to purchase hospital drugs.
Consultation on funding arrangements for beta-interferon for multiple sclerosis (MS).
Background Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in−vitro assays. Objectives: To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.
Further to our consultation letter of 24 December 2002, the following letter relates to: • the proposed prescribing guidelines…
Updated cost utility analysis for statins Scott Metcalfe Pharmac 30 January 2001 Pharmac estimates the cost-utility of providing statins to everyone with dyslipidaemia and > 10% 5-year absolute risk of cardiovascular events, at a proposed price of $0.45/day, is $1,630/QALY…
Purpose This paper examines the incremental benefits and costs of treating patients with familial hyperlipidaemia with simvastatin 40mg/day, over and above the net costs and…
Methods and Assumptions - costs and benefits of lipid modifying agents
(54 pages, 336 KB)
This paper describes a model which PHARMAC has developed to assess the costs and benefits of extending subsidy criteria for lipid-modifying agents (LMAs). The model assesses both need for…
Summary - cost utility analysis of the lipid modifying agents
(10 pages, 75 KB)
Net benefits of LMAs The benefits of LMAs can be measured in quality-adjusted life years saved (QALYS), which combine fatal with non-fatal events. Net quality-adjusted life years saved comprise: 1.…